U.S./EUROPEAN MUTUAL RECOGNITION TALKS FOR DEVICE APPROVALS ON HOLD UNTIL 1997 AT EARLIEST WHILE AGENCY EVALUATES THIRD-PARTY REVIEW PILOT PROGRAM
This article was originally published in The Gray Sheet
Medical device mutual recognition agreement negotiations between FDA and the European Union are on hold until 1997 at the earliest, according to FDAers and U.S. trade officials. Talks were delayed after FDA topsiders rejected a draft "concept paper" outlining a device approval MRA strategy that was negotiated by FDA and EU representatives in Washington, D.C. in November 1995.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.